Thomas Verstraeten | Managing Director

Thomas Verstraeten, Managing Director, P95

Dr Verstraeten is the founder of P95, a team of 15 epidemiologists, statisticians and analysts located across the globe.  With his team, he provides epidemiology and pharmacovigilance support to all stakeholders in vaccination, including industry, public health and academia. His research interests include pharmaco-epidemiology, biostatistics, and vaccinology in general. Recent projects he was involved in include meta-analyses of the safety and effectiveness of vaccines, quantitative benefit-risk assessment in both development and post-licensure application and modelling the burden of infectious diseases in large electronic databases. Prior to founding P95, Dr Verstraeten worked at the CDC as an EIS officer in the vaccine safety branch and was the head of the epidemiology and pharmacovigilance departments of GSK’s vaccine division.


DC Co-conference Day 2 April 4 @ 12:55

A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among the elderly

  • We searched the literature for clinical trials (CTs) including new adjuvant systems (AS01, AS02, AS03, or MF59), used in people of 50 years and older, published between January 1995 and September 2017.
  • 12 CTs were retained on AS01/AS02, AS03 and MF59 adjuvants, respectively, covering 92,123 subjects
  • This systematic literature review showed no overall increase in SAEs, fatalities, or unsolicited AEs following newly adjuvanted vaccines.
  • Higher rates for local or general AEs were observed for all newly adjuvanted vaccines, but AEs were mostly mild and transient.

back to speakers